Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + docetaxel
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination chemotherapy regimen, studied by Clinical Oncology Research Associates, consists of a fluoropyrimidine (either the oral prodrug capecitabine or intravenous fluorouracil) administered alongside the taxane docetaxel. The regimen is typically investigated in conjunction with concurrent radiotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). Capecitabine and fluorouracil act as antimetabolites that inhibit thymidylate synthase, thereby disrupting DNA synthesis and repair. Docetaxel works by stabilizing microtubules, which prevents their depolymerization and leads to cell cycle arrest and apoptosis. This specific protocol utilizes hypofractionated chest radiotherapy to enhance local tumor control while the chemotherapy agents provide both systemic activity and radiosensitization.
- Brand names
- Xeloda + Taxotere
- Other names
- fluorouracil + docetaxel5-FU + docetaxelXeloda + docetaxelcapecitabine + Taxoterechemotherapy-Clinical Oncology Research Associates-non-small cell lung cancer
02
Targets
TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on capecitabine + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + docetaxel.